Abstract
Induced therapeutic hypothermia is the one of the most effective tools against brain injury and inflammation. Even though its beneficial effects are well known, there are a lot of pitfalls to overcome, since the potential adverse effects of systemic hypothermia are still troublesome. Without the knowledge of the precise mechanisms of hypothermia, it will be difficult to tackle the application of hypothermia in clinical fields. Better understanding of the characteristics and modes of hypothermic actions may further extend the usage of hypothermia by developing novel drugs based on the hypothermic mechanisms or by combining hypothermia with other therapeutic modalities such as neuroprotective drugs. In this review, we describe the potential therapeutic targets for the development of new drugs, with a focus on signal pathways, gene expression, and structural changes of cells. Theapeutic hypothermia has been shown to attenuate neuroinflammation by reducing the production of reactive oxygen species and proinflammatory mediators in the central nervous system. Along with the mechanism-based drug targets, applications of therapeutic hypothermia in combination with drug treatment will also be discussed in this review.
Keywords: Hypothermia, pharmacotherapy, drug target, signal pathway, neuroinflammation, bloodbrain barrier (BBB), aneurysm surgery
Current Neuropharmacology
Title: Molecular and Cellular Pathways as a Target of Therapeutic Hypothermia: Pharmacological Aspect
Volume: 10 Issue: 1
Author(s): Hyung Soo Han, Jaechan Park, Jong-Heon Kim and Kyoungho Suk
Affiliation:
Keywords: Hypothermia, pharmacotherapy, drug target, signal pathway, neuroinflammation, bloodbrain barrier (BBB), aneurysm surgery
Abstract: Induced therapeutic hypothermia is the one of the most effective tools against brain injury and inflammation. Even though its beneficial effects are well known, there are a lot of pitfalls to overcome, since the potential adverse effects of systemic hypothermia are still troublesome. Without the knowledge of the precise mechanisms of hypothermia, it will be difficult to tackle the application of hypothermia in clinical fields. Better understanding of the characteristics and modes of hypothermic actions may further extend the usage of hypothermia by developing novel drugs based on the hypothermic mechanisms or by combining hypothermia with other therapeutic modalities such as neuroprotective drugs. In this review, we describe the potential therapeutic targets for the development of new drugs, with a focus on signal pathways, gene expression, and structural changes of cells. Theapeutic hypothermia has been shown to attenuate neuroinflammation by reducing the production of reactive oxygen species and proinflammatory mediators in the central nervous system. Along with the mechanism-based drug targets, applications of therapeutic hypothermia in combination with drug treatment will also be discussed in this review.
Export Options
About this article
Cite this article as:
Soo Han Hyung, Park Jaechan, Kim Jong-Heon and Suk Kyoungho, Molecular and Cellular Pathways as a Target of Therapeutic Hypothermia: Pharmacological Aspect, Current Neuropharmacology 2012; 10 (1) . https://dx.doi.org/10.2174/157015912799362751
DOI https://dx.doi.org/10.2174/157015912799362751 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Proteomic Analysis of Liver Preservation Solutions Prior to Liver Transplantation
Current Proteomics Lipoprotein (a) and Cardiovascular Risk: The Show Must go on
Current Medicinal Chemistry Cellular and Molecular Regulation of Inflammatory Pain, Nociception and Hyperalgesia - The Role of the Transcription Factor NF-κB as the Lynchpin Nocisensor: Hyperalgesic or Analgesic Effect?
Current Immunology Reviews (Discontinued) The Ultimate Outlier: Transitional Care for Persons with Dementia and BPSD
Current Alzheimer Research Efficacy and Safety of Bevacizumab in Glioblastomas
Current Medicinal Chemistry Update on the Role of Neutrophils in Atherosclerotic Plaque Vulnerability
Current Drug Targets Screening of Early and Late Onset Alzheimer’s Disease Genetic Risk Factors in a Cohort of Dementia Patients from Liguria, Italy
Current Alzheimer Research A Comprehensive Review on Hydrogels
Current Drug Delivery Astrocytic Target Mechanisms in Epilepsy
Current Medicinal Chemistry The Neuroprotective Effect of Ginkgo biloba Leaf Extract and its Possible Mechanism
Central Nervous System Agents in Medicinal Chemistry Possibilities of Poly(D,L-lactide-co-glycolide) in the Formulation of Nanomedicines Against Cancer
Current Drug Targets Development of FXR, PXR and CAR Agonists and Antagonists for Treatment of Liver Disorders
Current Topics in Medicinal Chemistry An Unusual Case of Reversible Empty Sella
Endocrine, Metabolic & Immune Disorders - Drug Targets Histone Deacetylase Inhibitors: Therapeutic Agents and Research Tools for Deciphering Motor Neuron Diseases
Current Medicinal Chemistry Dual Inhibitors of Monoamine Oxidase and Cholinesterase for the Treatment of Alzheimer Disease
Current Topics in Medicinal Chemistry Chemical Events Behind Leukoaraiosis: Medicinal Chemistry Offers New Insight into a Specific Microcirculation Disturbance in the Brain (a Chemical Approach to a Frequent Cerebral Phenotype)
Current Medicinal Chemistry Impact of Curcumin on Traumatic Brain Injury and Involved Molecular Signaling Pathways
Recent Patents on Food, Nutrition & Agriculture Electronic Fetal Heart Rate Monitoring: The Future
Current Women`s Health Reviews Inflammation: Beneficial or Detrimental After Spinal Cord Injury?
Recent Patents on CNS Drug Discovery (Discontinued) Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Current Neuropharmacology